Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 15/20 | 0.59 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.59 |
| ▸ | F9 | P00740 | 1/20 | 0.59 |
| ▸ | F10 | P00742 | 1/20 | 0.59 |
| ▸ | PLAT | P00750 | 1/20 | 0.59 |
| ▸ | F11 | P03951 | 1/20 | 0.59 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.59 |
| ▸ | F7 | P08709 | 1/20 | 0.59 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.59 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL643295 | 0.92 | CYP3A4 (0.57) | F2PRSS1F9F10PLAT | |
| SCHEMBL642291 | 0.90 | F2 (0.72) | F2PRSS1F9F10PLAT | |
| SCHEMBL642219 | 0.86 | CYP3A4 (0.71) | F2PRSS1F9F10PLAT | |
| SCHEMBL643578 | 0.85 | F2 (0.59) | F2PRSS1F9F10PLAT | |
| SCHEMBL641242 | 0.84 | F2 (0.82) | F2PRSS1F9F10PLAT | |
| SCHEMBL642144 | 0.83 | CYP3A4 (0.65) | F2PRSS1F9F10PLAT | |
| SCHEMBL643221 | 0.82 | CYP3A4 (0.54) | F2PRSS1F9F10PLAT | |
| SCHEMBL641197 | 0.82 | CYP3A4 (0.55) | F2PRSS1F9F10PLAT | |
| SCHEMBL643661 | 0.81 | CYP3A4 (0.59) | F2PRSS1F9F10PLAT | |
| SCHEMBL641518 | 0.77 | CYP3A4 (0.57) | F2PRSS1F9F10PLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011525487-A | — | — | 2011-09-22 | — | — | JP | claimed |
| US-20110130432-A1 | Heterocyclic Carboxamides For Use As Thrombin Inhibitors | ASTRAZENECA AB (SE) | 2011-06-02 | — | — | US | claimed |
| EP-2321301-A1 | NEW HETEROCYCLIC CARBOXAMIDES FOR USE AS THROMBIN INHIBITORS | AstraZeneca AB (SE) | 2011-05-18 | — | — | EP | claimed |
| WO-2009157860-A1 | NEW HETEROCYCLIC CARBOXAMIDES FOR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2009-12-30 | — | — | WO | claimed |
| US-8119673-B2 | Compounds 148 | ASTRAZENECA AB (SE) | 2012-02-21 | — | — | US | disclosed |
| US-8119673-B2 | Compounds 148 | ASTRAZENECA AB (SE) | 2012-02-21 | — | — | US | disclosed |
| US-8119673-B2 | Compounds 148 | ASTRAZENECA AB (SE) | 2012-02-21 | — | — | US | disclosed |
| US-20110130432-A1 | Heterocyclic Carboxamides For Use As Thrombin Inhibitors | ASTRAZENECA AB (SE) | 2011-06-02 | — | — | US | disclosed |
| US-20110130432-A1 | Heterocyclic Carboxamides For Use As Thrombin Inhibitors | ASTRAZENECA AB (SE) | 2011-06-02 | — | — | US | disclosed |
| US-20110130432-A1 | Heterocyclic Carboxamides For Use As Thrombin Inhibitors | ASTRAZENECA AB (SE) | 2011-06-02 | — | — | US | disclosed |
| EP-2321301-A1 | NEW HETEROCYCLIC CARBOXAMIDES FOR USE AS THROMBIN INHIBITORS | AstraZeneca AB (SE) | 2011-05-18 | — | — | EP | disclosed |
| WO-2009157860-A1 | NEW HETEROCYCLIC CARBOXAMIDES FOR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2009-12-30 | — | — | WO | disclosed |
| US-20090318517-A1 | Novel Compounds 148 | ASTRAZENECA AB (SE) | 2009-12-24 | — | — | US | disclosed |
| US-20090318517-A1 | Novel Compounds 148 | ASTRAZENECA AB (SE) | 2009-12-24 | — | — | US | disclosed |
| US-20090318517-A1 | Novel Compounds 148 | ASTRAZENECA AB (SE) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130432-A1 | Heterocyclic Carboxamides For Use As Thrombin Inhibitors | TFPI, TFPI2, SPINT2 | F2 19/4885PRSS1 4/4885F9 310/4885 |
| US-20090318517-A1 | Novel Compounds 148 | SERPINB1, SPINT2, TFPI | F2 32/4885PRSS1 4/4885F9 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.